Compare Cognizant Technology Solutions Corp (CTSH) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Novo Nordisk A/S — how do they compare? Cognizant Technology Solutions Corp trades at $59.53 (market cap $27.03B), while Novo Nordisk A/S trades at $38.38 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 6.1× Cognizant Technology Solutions Corp's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Novo Nordisk A/S for 116 Days on average.
| CTSH | NVO | |
|---|---|---|
Market Cap | $27.03B | $165.31B |
Volume | 9,883,888 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $86.70 | $63.98 |
52-Week Low | $38.73 | $35.29 |
Typical Hold Time | 57 Days | 116 Days |
Enterprise Value | $28.08B | $179.56B |
Dividend Yield | 2.2% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $57.07, down 0.26% on the day, with a bearish technical signal from moving averages. The company reported revenue of $21.11B in 2025 with a net income margin of 10.26%, and recent quarterly earnings have mostly beaten expectations. Analysts maintain a consensus price target of $64.25, with 45.1% recommending a buy. Positive news includes AI partnerships and workplace recognitions, but cash flow trends show volatility.
CTSH presents a mixed outlook: undervalued fundamentals with a P/E of 12.88 and strong profitability support upside potential, but technical weakness and competitive IT spending pressures pose risks. The stock's performance hinges on Q3 2026 earnings results due October 29, 2026, which could validate AI-driven growth initiatives or exacerbate bearish sentiment.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
